Background: Natalizumab has been recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with insufficient response to interferon-β or glatiramer acetate (disease-modifying treatments – DMT) or in aggressive MS. The pivotal trials were not designed to investigate natalizumab monotherapy in these patient populations. Aim: To investigate the efficacy of natalizumab after treatment failure of previous DMT and in highly active MS. Methods: A retrospective, multicenter study in Switzerland. Three major MS centers reported all RRMS patients who initiated natalizumab ≧12 months prior to study conduction. Results: 85 RRMS patients were included (72% female, mean age 37.3 years, mean Expanded Disability Status Scale 3.1; 88.2% were pretreated with DMT), and mean treatment duration with natalizumab was 18.4 ± 2.6 months. 79% of the patients were relapse-free during the observational period. The annualized relapse rate decreased from 2.0 ± 0.6 to 0.27 ± 0.2, and 92.9% were progression-free after 12 months (p < 0.001). The mean number of gadolinium-enhancing lesions decreased from 1.2 ± 1.2 to 0.1 ± 0.1 at 12 months’ follow-up (91.7% reduction).Discontinuation rate was 11.8% (7.1% for antibody positivity). Conclusions: Patients who initiate natalizumab after previous high disease activity experience a marked reduction of clinical and MRI disease activity.

Polman CH, O’Connor PW, Havrdova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910.
Yednock TA, Cannon C, Fritz L, et al: Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63–66.
Yousry TA, Major EO, Ryschkewitsch C, et al: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924–933.
European Medicine Agency (2006)
Rudick RA, Stuart WH, Calabresi PA, et al: Natalizumab plus interferon-β1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911–923.
Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231.
McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E: Defining interferon-β response status in multiple sclerosis patients. Ann Neurol 2004;56:548–555.
Sorensen PS, Tscherning T, Mathiesen HK, et al: Neutralizing antibodies hamper IFN-β bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681–1683.
Kappos L, Bates D, Hartung HP, et al: Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431–441.
Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O: Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006;13:471–474.
Carra A, Onaha P, Luetic B, et al: Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386–393.
Limmroth V, Putzki N: High-dose, frequently administered interferon-β. J Neurol Sci 2005;15:95–96.
Confavreux C, Vukusic S: Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 2004;106:263–269.
Rizvi SA, Agius MA: Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(suppl 6):S8–S14.
Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR: Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 2007;68:1524–1528.
Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V: Natalizumab is effective as second-line therapy in the treatment of relapsing remitting MS. Eur J Neurol 2009;16:424–426.
Oturai AB, Koch-Henriksen N, Petersen T, et al: Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009;16:420–423.
Hutchinson M, Kappos L, Calabresi PA, et al: The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405–415.
Gold R, Jawad A, Miller DH, et al: Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 2007;187:156–158.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.